{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T08:48:13Z","timestamp":1775292493135,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Although the safety and therapeutic efficacy of COVID\u201019 convalescent plasma (CCP) has been extensively evaluated, the safety of CCP donation has not been explored in a multi\u2010institutional context.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study design and methods<\/jats:title><jats:p>Nine blood collection organizations (BCOs) participated in a multi\u2010institutional donor hemovigilance effort to assess the safety of CCP donation. Donor adverse events (DAEs) were defined according to the Standard for Surveillance of Complications Related to Blood Donation, and severity was assessed using the severity grading tool. Multivariate analysis was performed to determine attributes associated with DAE severity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall DAE rate was 37.7 per 1000 donations. Repeat apheresis and apheresis\u2010na\u00efve donors experienced adverse event rates of 19.9 and 49.8 per 1000 donations, respectively. Female donors contributed 51.9% of CCP donations with a DAE rate of 49.4 per 1000 donations. The DAE rate for male donors was 27.4 per 1000 donations. Vasovagal reactions accounted for over half of all reported DAEs (51.1%). After adjustment, volume of CCP donated was associated with vasovagal reaction severity (odds ratio [OR] 6.5, 95% confidence interval [CI] 2.5\u201317.1). Donor age and donation history were also associated with DAE severity. Considerable differences in DAE types and rates were observed across the participating BCOs despite the use of standardized hemovigilance definitions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The safety of CCP donation appears comparable to that of conventional apheresis plasma donation with similar associated risk factors for DAE types and severity.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.16572","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T11:45:39Z","timestamp":1625571939000},"page":"2668-2676","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The safety of <scp>COVID<\/scp>\u201019 convalescent plasma donation: A <scp>multi\u2010institutional<\/scp> donor hemovigilance study"],"prefix":"10.1111","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6250-1797","authenticated-orcid":false,"given":"Joseph H.","family":"Cho","sequence":"first","affiliation":[{"name":"Medical Sciences Institute Versiti  Milwaukee Wisconsin USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srijana","family":"Rajbhandary","sequence":"additional","affiliation":[{"name":"Department of Research AABB  Bethesda Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1309-9770","authenticated-orcid":false,"given":"Nancy L.","family":"van Buren","sequence":"additional","affiliation":[{"name":"Innovative Blood Resources Division of New York Blood Center  St. Paul Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6081-4151","authenticated-orcid":false,"given":"Mark K.","family":"Fung","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine The University of Vermont Health Network  Burlington Vermont USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Al\u2010Ghafry","sequence":"additional","affiliation":[{"name":"New York Blood Center  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy L.","family":"Fridey","sequence":"additional","affiliation":[{"name":"American Red Cross Blood Services, Southern California Region  Pomona California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth A.","family":"Dy","sequence":"additional","affiliation":[{"name":"American Red Cross Biomedical Services  Washington District of Columbia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1814-9319","authenticated-orcid":false,"given":"Alyssa","family":"Ziman","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine David Geffen School of Medicine at UCLA  Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1602-5248","authenticated-orcid":false,"given":"George B.","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Plasma Protein Therapeutics Association  Annapolis Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1175-9579","authenticated-orcid":false,"given":"Richard R.","family":"Gammon","sequence":"additional","affiliation":[{"name":"Scientific, Medical, Technical Direction OneBlood  Orlando Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Reik","sequence":"additional","affiliation":[{"name":"Scientific, Medical, Technical Direction OneBlood  Orlando Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3270-4913","authenticated-orcid":false,"given":"James R.","family":"Stubbs","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille M.","family":"van Buskirk","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hany","family":"Kamel","sequence":"additional","affiliation":[{"name":"Vitalant  Scottsdale Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7759-0676","authenticated-orcid":false,"given":"Mary J.","family":"Townsend","sequence":"additional","affiliation":[{"name":"Vitalant  Scottsdale Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle P.","family":"Zeller","sequence":"additional","affiliation":[{"name":"Canadian Blood Services  Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome L.","family":"Gottschall","sequence":"additional","affiliation":[{"name":"Medical Sciences Institute Versiti  Milwaukee Wisconsin USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031893"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1088-9"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2020.08.001"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033700"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3939"},{"key":"e_1_2_9_7_1","article-title":"Convalescent plasma in patients admitted to hospital with COVID\u201019 (RECOVERY): a randomised, controlled, open\u2010label, platform trial","author":"Horby PW","year":"2021","journal-title":"MedRxiv"},{"key":"e_1_2_9_8_1","unstructured":"\u201cTrial Update: Recruitment for the CONCOR\u20101 trial is now complete.\u201d CONCOR\u20101.https:\/\/concor1.ca\/#intro. Accessed 18 May 2021."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140200"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16208"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16286"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12323"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14948"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15830"},{"key":"e_1_2_9_15_1","unstructured":"RajbhandaryS StubbsJR LandKJ WhitakerBIAABB donor hemovigilance report: 2012\u20132014 on behalf of the AABB US Donor Hemovigilance Working Group AABB Press 2016."},{"key":"e_1_2_9_16_1","unstructured":"AABB2012\u20132017 AABB donor hemovigilance highlights.AABB.https:\/\/www.aabb.org\/docs\/default-source\/default-document-library\/resources\/2012-2017-aabb-donor-hemovigilance-highlights.pdf?sfvrsn=e1a74b0_0. Accessed 18 May 2021"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01811.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03216.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.19719"},{"key":"e_1_2_9_20_1","unstructured":"Wall Street J 2020 U.S. seeks large\u2010scale expansion of blood\u2010plasma collection for Covid\u201019"},{"key":"e_1_2_9_21_1","unstructured":"Convalescent plasma COVID\u201019 (coronavirus) treatment.https:\/\/www.uscovidplasma.org. Accessed 18 May 2021."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02443.x"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.16572","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.16572","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.16572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:55:28Z","timestamp":1693202128000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.16572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1111\/trf.16572"],"URL":"https:\/\/doi.org\/10.1111\/trf.16572","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,6]]},"assertion":[{"value":"2021-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}